Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vanucizumab plus mFOLFOX-6 versus bevacizumab plus mFOLFOX-6 in first-line metastatic colorectal cancer
2013-005108-32Phase 2Terminated
- Sponsor
- Roche
- Start
- May 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of faricimab, bevacizumab, oxaliplatin, folinic acid and fluorouracil in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started May 2014; status: terminated.
02
Drugs
faricimabbevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-005108-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005108-32.